Enveric Biosciences, Inc. Income Charts

2 years of history · ending 2025-12-31 · SEC EDGAR

Source:10-K · 10-Q

Revenue, Gross Profit, Operating Income & Net Income

Margin (%)

Operating Expenses

Income Breakdown

Revenue
$-106
Cost of Revenue
Gross Profit
R&D
$3M
SG&A
D&A
$201K
Operating Income
$-9M
EBITDA
$-9M
Interest Expense
Other Income/Expense
$2K
Pretax Income
$-9M
Tax Provision
$9K
Net Income
$-9M
Gross Margin
Operating Margin
8277781.1%
Net Margin
8275459.4%
Effective Tax Rate
-0.1%
Deferred Tax Assets
Deferred Tax Liabilities
DTA Valuation Allowance
$16M
Tax Credit Carryforwards
$290K
NOL Carryforwards
$14M
ETR (Continuing Operations)
0.1%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
-2.1%
ETR Foreign Differential (pp)
2.1%
Operating Lease Cost
Revenue YoY Variation
-148.4%
Income YoY Variation
8.9%
No segment data available for this ticker. Source: quarterchart.com.